Regulatory & Legal

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

A new series from A3 and BBC StoryWorks moves beyond efficiency to show how automation is augmenting human lives in healthcare, education, and more.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

Lufax names Xiang Ji as its new CEO amid major financial struggles. The move signals a tighter grip from controlling shareholder Ping An Group.

A new program in Michigan uses AI to analyze existing CT scans, detecting silent heart risks and connecting patients to care before symptoms even appear.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

Profitable and with little debt, this holding company is leveraging a diverse portfolio as it prepares for a major stock market uplist. Here's a closer look.

With a new regulatory chief, Ray Therapeutics accelerates its mission to bring its goggle-free optogenetic therapies for blindness through clinical trials.

Prestigious toxicology awards recognize UL Research Institutes' vital work on vaping health risks and innovative methods for assessing chemical safety.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

With 23,000 metres of drilling, Copper Giant aims to unlock one of the world's largest undeveloped copper caches, vital for the energy transition.

Ahead of its March 3 earnings call, 908 Devices' strong preliminary results and focus on handheld tech signal a pivotal year for the security innovator.

A fatal crash and a spike in deaths have prompted a stark warning: the mix of jets, helicopters, and drones in our airspace is a growing global threat.

India's car-sharing leader posts a record quarter, slashing losses by 91% without marketing spend, and now eyes a US market uplisting and new capital.

Ascend Elements' award to TDK Ventures reveals a new VC model, where hands-on partnership is key to building a secure, circular battery supply chain.

Fresh off a $1.1B IPO and a #1 GreenTech ranking, BETA Technologies faces investors to prove its electric aviation vision is commercially viable.

Real estate giant Kennedy Wilson agrees to an all-cash acquisition by its CEO and Fairfax Financial, offering a 46% premium to go private.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

Warner Bros. Discovery pushes for a Netflix merger but opens a one-week window for Paramount Skydance to fix its flawed bid. A bidding war looms.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.